VANCOUVER, Canada— iCo Therapeutics Inc. (TSX-V: ICO) is pleased to announce that the company has been selected as one of Canada’s Top 10™ Competition winners. Top 10™ winners are chosen by an independent expert panel of Canadian and U.S. venture capitalists. The panel can be viewed at http://www.topcanadiancompanies.ca/jury/lifesciences.html.
Competition winners may participate in a series of investment forums in select cities across the U.S. Developed together with key sponsors, partners and the Canadian consulates in each city, the forums expose the Top 10™ companies to an exclusive opportunity to present to top tier U.S. and Canadian venture capitalists, licensing executives and potential strategic partners in a series of invitation only events.
“I continue to be impressed by the quality of companies that I see coming out of Canada,” says Bernhardt Zeisig, Partner, Cycle Ventures LLC. “Because of programs like this, I get to review companies that I would normally not see. This competition is an effective way to put companies in front of investors like us.”
About Canada’s Top 10™ Competition
The vision for the Canada’s Top 10™ is to be Canada’s premier investment oriented competition by selecting the best potential investments in Canada for investors and providing high value added services to companies to increase their chances of success, both as they source investment and as they grow and compete in the global environment. Since its inception, competition alumni have secured more than $600M in venture capital financing. http://www.topcanadiancompanies.com/.
About iCo Therapeutics
iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications. iCo has exclusive worldwide rights to three products: iCo-007, moving into Phase II for the treatment of DME, iCo-008; a product with Phase II clinical history to be developed for severe ocular allergies and age-related macular degeneration; and iCo-009, an oral formulation of Amphotericin B for sight and life-threatening diseases. iCo-009 also represents a new drug delivery technology with the potential to reprofile other parenteral administered drugs to the oral route of administration. iCo was recently awarded a Gold Leaf Award as the Early Stage Company of the Year from BIOTECanada and trades on the TSX Venture Exchange under the symbol “ICO”. For more information, visit the Company website at: www.icotherapeutics.com
No regulatory authority has approved or disapproved the content of this release. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
Forward Looking Statements
Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on iCo Therapeutics’ current beliefs as well as assumptions made by and information currently available to iCo Therapeutics and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by iCo Therapeutics in its public securities filings; actual events may differ materially from current expectations. iCo Therapeutics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.